1
Total investments
1
Early stage
0
Mid stage
0
Late stage
7y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
2019
Allero Therapeutics is a Dutch biotech company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance.
Our proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege.
Experience · 3 entries
All (3)
Investments (1)
Founder (1)
Board (1)
2019
Board Member
2019
Allero Therapeutics is a Dutch biotech company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance.
Our proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege.
2018
K
Koala Life Sciences
Founder
2018
Investment Manager
2018
Swanbridge Capital is a Rotterdam based venture capital fund actively investing in young, high potential companies active in the field of therapeutics, diagnostics and medical devices. We are committed to invest in companies that are in a very early stage of development and still need to generate Proof of Concept for their technology. Our investments go beyond financial investments since we work very closely with our portfolio companies and take an active role in their business processes.
For more information visit www.swanbridgecapital.nl